NASDAQ: SNDX Syndax Pharmaceuticals Inc 8-K

Syndax raises $250M through convertible notes at 35% premium to fund R&D and commercialization

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SNDX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 5, 2026 3:52 PM